PRC
CRSP icon

Pearl River Capital’s CRISPR Therapeutics CRSP Stock Holding History

Pearl River Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-26,090
Closed -$1.41M – 94
2024
Q2 		$1.41M Buy
26,090
+20,132
+338% +$1.16M 0.22% 135
2024
Q1 		$406K Sell
5,958
-794
-12% -$56.8K 0.06% 332
2023
Q4 		$423K Buy
+6,752
New +$373K 0.07% 351
2021
Q4 		– Sell
-2,862
Closed -$320K – 445
2021
Q3 		$320K Buy
+2,862
New +$359K 0.09% 309
2019
Q2 		– Sell
-7,048
Closed -$252K – 316
2019
Q1 		$252K Buy
+7,048
New +$244K 0.63% 9

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Pearl River Capital's CRSP Position: Q3 2024 in Review

Pearl River Capital sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 26,090 shares — an estimated $1.41M sold.

Pearl River Capital first reported a position in CRSP in Q1 2019 and held it in 5 quarters. The position peaked at $1.41M in Q2 2024. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

  • Pearl River Capital reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pearl River Capital sold 26,090 CRISPR Therapeutics shares in Q3 2024, an estimated $1.41M.
  • Pearl River Capital first reported a position in CRISPR Therapeutics in Q1 2019 and held it in 5 quarters.
  • Pearl River Capital's CRISPR Therapeutics position peaked at $1.41M in Q2 2024.
  • 416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Pearl River Capital's 13F filing for Q3 2024.